Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 159

Results For "test"

2335 News Found

ProBioGen enters into master service agreement with NextPoint Therapeutics
News | August 18, 2022

ProBioGen enters into master service agreement with NextPoint Therapeutics

The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.


Yashoda Hospitals successfully performs bariatric surgery
Hospitals | August 15, 2022

Yashoda Hospitals successfully performs bariatric surgery

Man lost 54 Kgs in 6 months with MGB procedure


SPARSH Hospital organises a walkathon to create awareness on organ donation
Hospitals | August 15, 2022

SPARSH Hospital organises a walkathon to create awareness on organ donation

Donor privilege cards given to the families of all the donors from across Karnataka as a token of appreciation


Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
News | August 13, 2022

Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer

Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease


We must be careful in adopting global technological practices, says Union Health Secretary
Digitisation | August 13, 2022

We must be careful in adopting global technological practices, says Union Health Secretary

Urged stakeholders to come up with similar digital platforms and create homegrown best practices where Indian methods and Indian solutions dominate the digital spaces


JB Pharma records revenue growth of 30% in Q1 FY23
News | August 09, 2022

JB Pharma records revenue growth of 30% in Q1 FY23

Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23


ENHERTU approved in the U.S. as the first HER2 directed for low metastatic breast cancer
Drug Approval | August 09, 2022

ENHERTU approved in the U.S. as the first HER2 directed for low metastatic breast cancer

Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy


Creoptix launches new WAVEcontrol to deliver automated and label-free analysis for biologics drug-discovery
Digitisation | August 04, 2022

Creoptix launches new WAVEcontrol to deliver automated and label-free analysis for biologics drug-discovery

The WAVEsystem with the WAVEcontrol 4.0 embedded


LYNPARZA approved in the EU as adjuvant treatment for early breast cancer
Drug Approval | August 04, 2022

LYNPARZA approved in the EU as adjuvant treatment for early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients


PIB: Quality control of Ayush drugs
Policy | August 03, 2022

PIB: Quality control of Ayush drugs